Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SurroMed Inc.
Amidst a slew of disappointing IPOs, the moderate success of Genomic Health's IPO signals investor interest in a new diagnostics model: a combination product/service business -- technologically agnostic -- focused on coming up with an answer to a specific yes/no question that will either lead to or discourage an expensive therapy by a specialty physician audience. Several other start-ups are following the same model.
VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business model
Five years after the genomics bubble burst and financing doors shut, a small window may be opening for research tool suppliers that help pharma improve R&D efficiency and cost structure. But clinically-oriented research companies face particular challenges, notably how to build a business where customer adoption is slow but technology is evolving rapidly and investors are impatient.
Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- PPD Inc
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.